Business
Alkermes Showcases Research from Psychiatry Portfolio at Psych Congress
̶ Clinical, Epidemiology and Health Economics and Outcomes Research Shared at Key Psychiatry Conference ̶ DUBLIN, Sept. 20, 2022 /PRNewswire/ -- Alkermes plc
About this update from Alkermes Plc
[{"type":"text","content":"̶ Clinical, Epidemiology and Health Economics and Outcomes Research Shared at Key Psychiatry Conference ̶\nDUBLIN, Sept. 20, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry portfolio at Psych Congress, which began on Sept. 17 and concludes today, Sept. 20 in New Orleans.\n\"Alkermes is committed to advancing our understanding of serious mental illnesses and adding to the body of knowledge around our portfolio of medicines for people living with schizophrenia or bipolar I disorder,\" said Craig Hopkinson, M.D., Chief Medical Officer and Executive Vice President of Research & Development at Alkermes. \"We are excited to engage with healthcare professionals and thought leaders at Psych Congress, a preeminent event in the field of psychiatry, and look forward to further collaborating in the advancement of mental health research.\"\nHighlights of the presentations include:\nPoster 27: Olanzapine/Samidorphan in Young Adults with Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder Who Are Early in Illness: Results of the ENLIGHTEN-Early StudyPoster 37: Observational Study of Long-Acting Injectables in Schizophrenia (OASIS Study): Study Design and Interim Demographics and Baseline CharacteristicsPoster 39: Long-Term Safety and Symptom Trajectory with Aripiprazole Lauroxil in Female Patients with Schizophrenia: A Post Hoc AnalysisPoster 114: Clinical, Economic, and Humanistic Outcomes Associated with Obesity Among Adults with Bipolar I Disorder: Analysis of National Health and Wellness Survey DataPoster 146: LATITUDE: Long-Acting Antipsychotic Treatments in Community Telepsychiatry: Knowledge, Attitudes, and Perceived BarriersAbout LYBALVI® (olanzapine and samidorphan)LYBALVI® (olanzapine and samidorphan) is a once-daily, oral atypical antipsychotic drug approved in the U.S. for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. LYBALVI is composed of olanzapine, an established antipsychotic agent, co-formulated with samidorphan, a new chemical entity, in a single bilayer tablet. LYBALVI is available in fixed dosage strengths composed of 10 mg of samidorphan and 5 mg, 10 ...